Edwards Lifesciences Corp (NYSE:EW) VP Robert W.A. Sellers sold 12,020 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $131.03, for a total transaction of $1,574,980.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of Edwards Lifesciences Corp (NYSE EW) traded up $0.38 during trading hours on Tuesday, reaching $127.08. 2,466,563 shares of the company were exchanged, compared to its average volume of 1,356,402. The company has a market capitalization of $26,980.00, a P/E ratio of 44.13, a price-to-earnings-growth ratio of 2.01 and a beta of 0.63. Edwards Lifesciences Corp has a 52 week low of $89.20 and a 52 week high of $138.48. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. The company had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. Edwards Lifesciences’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.75 earnings per share. equities analysts anticipate that Edwards Lifesciences Corp will post 4.42 earnings per share for the current fiscal year.
Several analysts have issued reports on EW shares. JPMorgan Chase & Co. downgraded shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Barclays raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Cowen set a $135.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Sunday, December 10th. SunTrust Banks set a $124.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research note on Friday, December 8th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and an average price target of $139.25.
A number of large investors have recently modified their holdings of the stock. Advisory Services Network LLC raised its stake in Edwards Lifesciences by 0.9% in the second quarter. Advisory Services Network LLC now owns 12,565 shares of the medical research company’s stock worth $1,486,000 after buying an additional 112 shares in the last quarter. Kingfisher Capital LLC raised its stake in Edwards Lifesciences by 1.9% in the second quarter. Kingfisher Capital LLC now owns 8,454 shares of the medical research company’s stock worth $1,000,000 after buying an additional 159 shares in the last quarter. Aspen Investment Management Inc raised its stake in Edwards Lifesciences by 10.2% in the second quarter. Aspen Investment Management Inc now owns 4,038 shares of the medical research company’s stock worth $477,000 after buying an additional 375 shares in the last quarter. Resources Investment Advisors Inc. raised its stake in Edwards Lifesciences by 66.0% in the fourth quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock worth $132,000 after buying an additional 465 shares in the last quarter. Finally, Pacer Advisors Inc. raised its stake in Edwards Lifesciences by 10.4% in the third quarter. Pacer Advisors Inc. now owns 5,312 shares of the medical research company’s stock worth $581,000 after buying an additional 499 shares in the last quarter. 81.52% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/06/robert-w-a-sellers-sells-12020-shares-of-edwards-lifesciences-corp-ew-stock.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.